Firm’s income from operations within the quarter grew 15% to Rs 5,842 crore versus Rs 5,086 crore in Q1FY25.
The PAT was 11% larger on a sequential foundation versus Rs 390 crore in Q4FY25 whereas the topline elevated 4.5% over Rs 5,592 reported by the corporate in Q4FY25.
The earnings have been introduced after market hours and Apollo Hospitals shares ended with minor downtick at Rs 7,253 on the NSE.
Phase income
The corporate earned its revenues from healthcare providers, Retail well being & diagnostics, Digital well being & pharmacy distribution and in addition as different earnings.
— Healthcare providers income stood at Rs 2,974 crore in Q1FY26 versus Rs 2,843 crore in Q4FY25 and Rs 2,654 crore in Q1FY25.
— Retail well being & diagnostics income stood at Rs 435 crore in Q1FY26 versus Rs 394 crore in Q4FY25 and Rs 366 crore in Q1FY25.
— Digital well being & pharmacy distribution income stood at Rs 2,472 crore in Q1FY26 versus Rs 2,376 crore in Q4FY25 and Rs 2,082 crore in Q1FY25.
Additionally Learn: Nykaa Q1 Outcomes: Cons PAT soars 79% YoY to Rs 24 crore, income jumps 23%
Q1 Bills
The corporate’s bills have been reported at Rs 5,313 crore, up on a YoY and QoQ foundation. Within the earlier quarter, Apollo Hospitals had reported bills of Rs 5,148 crore whereas Rs 4,704 crore within the yr in the past interval. The bills have been made on materials utilized by the hospital, purchases of stock-in-trade, worker advantages and as finance value.
Acquisition
The corporate’s Board of Administrators immediately accepted an funding of Rs 8.5 crore for buying 85 lakh fairness shares of Apollo Gleneagles PET-CT Non-public Restricted (AGPCL) from its current shareholder, Parkway Healthcare (Mauritius) PTE Restricted, representing capital of AGPCL.
Additionally Learn: NSDL Q1 Outcomes: Cons PAT jumps 15% YoY to Rs 90 crore regardless of 7% drop in income
(Disclaimer: Suggestions, options, views and opinions given by the consultants are their very own. These don’t symbolize the views of Financial Instances)
